{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Colon%2FRectal+Cancer+Rectal+Cancer&page=22",
    "query": {
      "condition": "Colon/Rectal Cancer Rectal Cancer",
      "page": 22
    },
    "page_size": 10
  },
  "pagination": {
    "page": 22,
    "page_size": 10,
    "total_count": 2447,
    "total_pages": 245,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Colon%2FRectal+Cancer+Rectal+Cancer&page=23&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Colon%2FRectal+Cancer+Rectal+Cancer&page=21&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T14:51:33.707Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05839951",
      "title": "An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Metastatic Colorectal Cancer (mCRC)"
      ],
      "interventions": [
        {
          "name": "Regorafenib (BAY73-4506, Stivarga®)",
          "type": "DRUG"
        },
        {
          "name": "TAS-102 (trifluridine and tipiracil, Lonsurf®)",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 818,
      "start_date": "2023-04-24",
      "completion_date": "2025-04-30",
      "has_results": false,
      "last_update_posted_date": "2025-11-12",
      "last_synced_at": "2026-11-15T14:51:33.707Z",
      "location_count": 1,
      "location_summary": "Whippany, New Jersey",
      "locations": [
        {
          "city": "Whippany",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05839951"
    },
    {
      "nct_id": "NCT04668872",
      "title": "Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Colon Cancer Liver Metastasis",
        "Colon Cancer",
        "Adenocarcinoma of the Colon",
        "Adenocarcinoma of the Rectum",
        "Liver Metastasis Colon Cancer",
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Y90 TARE",
          "type": "RADIATION"
        },
        {
          "name": "PET/CT",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "PET/MRI",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2020-12-07",
      "completion_date": "2026-12-07",
      "has_results": false,
      "last_update_posted_date": "2026-03-12",
      "last_synced_at": "2026-11-15T14:51:33.707Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04668872"
    },
    {
      "nct_id": "NCT03800602",
      "title": "Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Adenocarcinoma",
        "Metastatic Microsatellite Stable Colorectal Carcinoma",
        "Refractory Colorectal Carcinoma",
        "Stage IV Colorectal Cancer",
        "Stage IVA Colorectal Cancer",
        "Stage IVB Colorectal Cancer",
        "Stage IVC Colorectal Cancer",
        "Colorectal Cancer Metastatic"
      ],
      "interventions": [
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2019-01-15",
      "completion_date": "2021-09-04",
      "has_results": true,
      "last_update_posted_date": "2024-09-05",
      "last_synced_at": "2026-11-15T14:51:33.707Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03800602"
    },
    {
      "nct_id": "NCT06397651",
      "title": "A Randomised Controlled Trial to Evaluate the Impact of Complement Theory's Live CoActive Exercise Coaching and Personalized Digital Application on Cancer Survivors' Quality of Life",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer",
        "Lung Cancer",
        "Prostate Cancer",
        "Colorectal Cancer",
        "Other Cancer"
      ],
      "interventions": [
        {
          "name": "Complement Theory's Live CoActive Exercise Coaching and Personalized Digital Application",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Digital application with expert guidelines on lifestyle modification",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Complement Theory Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 146,
      "start_date": "2024-05-12",
      "completion_date": "2026-02-28",
      "has_results": false,
      "last_update_posted_date": "2025-12-17",
      "last_synced_at": "2026-11-15T14:51:33.707Z",
      "location_count": 1,
      "location_summary": "Dover, Delaware",
      "locations": [
        {
          "city": "Dover",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06397651"
    },
    {
      "nct_id": "NCT04069702",
      "title": "Virtual Reality for Improving Pain and Distress in Patients With Advanced Stage Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "VR Blue",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 20,
      "start_date": "2020-03-12",
      "completion_date": "2021-07-19",
      "has_results": true,
      "last_update_posted_date": "2023-07-10",
      "last_synced_at": "2026-11-15T14:51:33.707Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04069702"
    },
    {
      "nct_id": "NCT02890069",
      "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "PDR001",
          "type": "BIOLOGICAL"
        },
        {
          "name": "LCL161",
          "type": "DRUG"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Panobinostat",
          "type": "DRUG"
        },
        {
          "name": "QBM076",
          "type": "DRUG"
        },
        {
          "name": "HDM201",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 298,
      "start_date": "2016-10-14",
      "completion_date": "2022-02-22",
      "has_results": false,
      "last_update_posted_date": "2023-01-11",
      "last_synced_at": "2026-11-15T14:51:33.707Z",
      "location_count": 9,
      "location_summary": "Santa Monica, California • Baltimore, Maryland • Boston, Massachusetts + 6 more",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02890069"
    },
    {
      "nct_id": "NCT00408551",
      "title": "Chemotherapy and Internal Radiation in Treating Patients With Colorectal Cancer That Has Spread to the Liver",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Metastatic Cancer"
      ],
      "interventions": [
        {
          "name": "floxuridine",
          "type": "DRUG"
        },
        {
          "name": "fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "irinotecan hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "leucovorin calcium",
          "type": "DRUG"
        },
        {
          "name": "oxaliplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Goshen Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2005-11",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-12-19",
      "last_synced_at": "2026-11-15T14:51:33.707Z",
      "location_count": 1,
      "location_summary": "Goshen, Indiana",
      "locations": [
        {
          "city": "Goshen",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00408551"
    },
    {
      "nct_id": "NCT05806931",
      "title": "Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colon Cancer",
        "Rectal Cancer"
      ],
      "interventions": [
        {
          "name": "TAS-102, oxaliplatin, irinotecan with bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rutgers, The State University of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2023-05-17",
      "completion_date": "2027-05-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-18",
      "last_synced_at": "2026-11-15T14:51:33.707Z",
      "location_count": 9,
      "location_summary": "Elizabeth, New Jersey • Jersey City, New Jersey • Lakewood, New Jersey + 5 more",
      "locations": [
        {
          "city": "Elizabeth",
          "state": "New Jersey"
        },
        {
          "city": "Jersey City",
          "state": "New Jersey"
        },
        {
          "city": "Lakewood",
          "state": "New Jersey"
        },
        {
          "city": "Livingston",
          "state": "New Jersey"
        },
        {
          "city": "Long Branch",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05806931"
    },
    {
      "nct_id": "NCT07071961",
      "title": "Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Regorafenib",
        "High Risk Patients"
      ],
      "interventions": [
        {
          "name": "Regorafenib (CT)",
          "type": "DRUG"
        },
        {
          "name": "Lorigerlimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2026-02-11",
      "completion_date": "2029-05-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-27",
      "last_synced_at": "2026-11-15T14:51:33.707Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07071961"
    },
    {
      "nct_id": "NCT04744831",
      "title": "Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "DS-8201a 5.4 mg/kg Q3W",
          "type": "DRUG"
        },
        {
          "name": "DS-8201a 6.4 mg/kg Q3W",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 122,
      "start_date": "2021-03-05",
      "completion_date": "2024-12-04",
      "has_results": true,
      "last_update_posted_date": "2026-01-14",
      "last_synced_at": "2026-11-15T14:51:33.707Z",
      "location_count": 9,
      "location_summary": "Chicago, Illinois • Louisville, Kentucky • Boston, Massachusetts + 5 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04744831"
    }
  ]
}